Back
Abivax Becomes $23B Target After 1,681% Stock Gain
Back
Stock News
Themes
Abivax Becomes $23B Target After 1,681% Stock Gain
Donald Trump
Abivax Becomes $23B Target After 1,681% Stock Gain
Edgen Stock
·
Jan 09 2026, 18:59
Share to
Share to
Copy link
ABVX
+1.29%
source:
[1] Abivax’s stock surged to become a prime biotech takeover target
Recommend
Regentis Reports Breakthrough Cartilage Regeneration in 2-Year GelrinC Study
Jan 20 2026, 14:36
ServiceNow Taps OpenAI to Embed AI Agents in Enterprise Software
Jan 20 2026, 14:32
Bristol Myers Taps Microsoft AI for Lung Cancer Detection
Jan 20 2026, 14:26
Edgen Stock·Jan 09 2026, 18:59Edgen Stock·Jan 09 2026, 18:59
Edgen Stock·Jan 09 2026, 18:59